Early benefit assessment reveals weaknesses in the development of new drugs

(Institute for Quality and Efficiency in Health Care) In the British Medical Journal, IQWiG researchers analyse the first 216 AMNOG assessments of new drugs and derive proposals for more targeted drug development.